Target treatment and adverse effects of early breast cancer
The impact of the target on the treatment of breast cancer varies from one individual to another, but is significantly positive overall. For HeR2 positive breast cancer patients, target-oriented treatment can effectively control the progress of tumours. It significantly improves the mitigation and survival of patients by acting specifically on HeR2 receptors and disrupting the growth signal transmission of cancer cells. Target-oriented treatment can more precisely attack tumour cells and reduce damage to normal cells than traditional treatment, thus reducing the side effects of treatment. A number of clinical studies have shown that the non-progressive life and total survival of HeR2-positive breast cancer patients receiving targeted treatment has been significantly extended. For example, the use of a single target-oriented drug, such as tratophos, can reduce the risk of re-emergence of patients and significantly extend their lifespan. Targets are often used in combination with other treatment methods, such as surgery, chemotherapy and treatment, to create synergies and further improve treatment effectiveness. In the new assisted treatment, the target-oriented combination of chemotherapy can reduce tumours, increase the chances of surgical removal and increase the breast protection rate. In post-operative assisted treatment, combined treatment reduces the risk of relapse and increases the long-term survival chances of patients. Target treatment, however, is not effective for all patients. Some patients may experience drug resistance, leading to reduced treatment outcomes. In addition, the relatively high cost of targeting treatment may also place a financial burden on patients. In the light of the above, the target-oriented treatment of breast cancer has a better effect, but the specific efficacy needs to be assessed on the basis of the individual situation of the patient. In treatment, it is important to note that there may be differences in the side effects of different target-to-pharmaceuticals, and that the severity of side effects varies from one individual to another. During the treatment of the target, the patient should closely monitor his/her physical condition and, if he/she is not in a position to report to the doctor in a timely manner so that he/she can adjust the treatment and mitigate the side effects, the doctor will develop a personalized treatment based on a combination of the patient ‘ s tumour characteristics and state of health, among other factors. Patients may suffer from heart arrest, chest distress, heart disorder and, in serious cases, heart failure. During treatment, doctors usually closely monitor the heart function of the patient, such as regular electrocardiograms, cardiac ultrasound, etc. 1. Disgusting, vomiting: this is one of the more common side effects. Targeting drugs can stimulate gastrointestinal tracts, causing discomfort, vomiting, etc. Diarrhoea: Some patients are treated for diarrhea after the target, which in serious cases may affect their quality of life and nutritional intake. Doctors may treat laxatives to the extent of diarrhoea. 1. Skin rashes: Often manifested in red spots, rubles, itching, etc. The severity of the rash varies from person to person, which may affect the appearance and comfort of the patient. 2. Foot-and-hand syndrome: Patients may experience symptoms such as pain, bruises and skin-skinning that affect their daily activities. 1. Declining white cells: Target-oriented treatment may lead to a decrease in white cell numbers, lower patient immunity and increased risk of infection. 2. Anaemia: Some suffer from anaemia, such as inactivity, dizziness, etc. 1. Weaknesses: patients are often tired and weak, affecting day-to-day activities and quality of life. 2. Heat: A small number of patients may have fever in the course of treatment and other causes, such as infection, need to be excluded.
